Literature DB >> 2825976

Profiles of carbohydrate-metabolizing enzymes in human hepatocellular carcinomas and preneoplastic livers.

K Taketa1, J Shimamura, M Ueda, Y Shimada, K Kosaka.   

Abstract

Activities of key carbohydrate-metabolizing enzymes in biopsied human tissues of hepatocellular carcinoma and related conditions were determined by established methods. Among the enzymes analyzed, fetal-type liver enzymes (low-Km hexokinase, glucose 6-phosphate dehydrogenase, and pyruvate kinase-M2) showed increased activities, and adult-type liver enzymes [glucose 6-phosphatase, fructose 1,6-bisphosphatase, high-Km hexokinase (or glucokinase), and pyruvate kinase-L] showed decreased activities, resulting in undifferentiated enzyme patterns not only in fetal livers and hepatocellular carcinomas but also in livers of acute and chronic hepatitis and liver cirrhosis with or without tumors. Hepatocellular carcinomas showed a general tendency of having greater enzyme deviations than hepatitic and cirrhotic livers. The extent of the enzyme deviation in hepatocellular carcinomas varied considerably from one enzyme to another for each tumor tissue as compared with that in the benign liver diseases. Thus, the phenotypic heterogeneity was important for discriminating between the neoplastic and inflammatory changes in differentiation markers. The enzyme patterns of tumors and their corresponding host cirrhotic livers were unrelated, suggesting that the cirrhotic liver has a significance as preneoplastic state only in terms of having a high incidence of evolving hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2825976

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

Review 1.  Oxidative phosphorylation enzymes in normal and neoplastic cell growth.

Authors:  F Capuano; F Guerrieri; S Papa
Journal:  J Bioenerg Biomembr       Date:  1997-08       Impact factor: 2.945

2.  Marker Enzymes of Rat Chemical Hepatocarcinogenesis in Human Liver Tumors.

Authors:  Zsuzsa Schaff; Károly Lapis; András Jeney
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

Review 3.  Glucose metabolic phenotype of pancreatic cancer.

Authors:  Anthony K C Chan; Jason I E Bruce; Ajith K Siriwardena
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

4.  Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma.

Authors:  Y-C Shen; D-L Ou; C Hsu; K-L Lin; C-Y Chang; C-Y Lin; S-H Liu; A-L Cheng
Journal:  Br J Cancer       Date:  2012-12-20       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.